 | • レポートコード：MRC2302E0082 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、221ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社では、2021年に7,391.22百万ドルであった世界の開放隅角緑内障治療薬市場規模が、2022年に7,987.70百万ドルに達し、2027年には年平均成長率8.32%で11,942.29百万ドルまで成長すると予測しています。当調査レポートでは、開放隅角緑内障治療薬の世界市場の現状について調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、競争状況などの構成でまとめております。セグメント分析では、製品別（非PGA、PGA）、薬剤クラス別（ビマトプロスト、ラタノプロスト、トラボプロスト、ウノプロストン）、エンドユーザー別（外来手術センター、病院、眼科クリニック）、流通チャネル別（病院薬局、オンライン薬局、小売薬局）、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）の情報が含まれています。なお、当市場の主要企業には、AbbVie Inc.、Aerie Pharmaceuticals Inc、Alcon Inc.、AqueSys、Bausch Health Co Inc、D.Western Therapeutics Institute Inc、EyePoint Pharmaceuticals,Inc、Fera Pharmaceuticals、Hikma Pharmaceuticals Plc、Iridex Corporation、Laboratories Sophia、Merck and Co. Inc.、Nicox SA、Novartis AG、Ocuphire Pharma Inc、Otsuka Pharmaceutical Co. Ltd.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の開放隅角緑内障治療薬市場規模：製品別 - 非PGAの市場規模 - PGAの市場規模 ・世界の開放隅角緑内障治療薬市場規模：薬剤クラス別 - ビマトプロストの市場規模 - ラタノプロストの市場規模 - トラボプロストの市場規模 - ウノプロストンの市場規模 ・世界の開放隅角緑内障治療薬市場規模：エンドユーザー別 - 外来手術センターにおける市場規模 - 病院における市場規模 - 眼科クリニックにおける市場規模 ・世界の開放隅角緑内障治療薬市場規模：流通チャネル別 - 病院薬局の市場規模 - オンライン薬局の市場規模 - 小売薬局の市場規模 ・世界の開放隅角緑内障治療薬市場規模：地域別 - 南北アメリカの開放隅角緑内障治療薬市場規模 アメリカの開放隅角緑内障治療薬市場規模 カナダの開放隅角緑内障治療薬市場規模 ブラジルの開放隅角緑内障治療薬市場規模 … - アジア太平洋の開放隅角緑内障治療薬市場規模 日本の開放隅角緑内障治療薬市場規模 中国の開放隅角緑内障治療薬市場規模 インドの開放隅角緑内障治療薬市場規模 韓国の開放隅角緑内障治療薬市場規模 台湾の開放隅角緑内障治療薬市場規模 … - ヨーロッパ/中東/アフリカの開放隅角緑内障治療薬市場規模 イギリスの開放隅角緑内障治療薬市場規模 ドイツの開放隅角緑内障治療薬市場規模 フランスの開放隅角緑内障治療薬市場規模 ロシアの開放隅角緑内障治療薬市場規模 … - その他地域の開放隅角緑内障治療薬市場規模 ・競争状況 ・企業情報 |
The Global Open-Angle Glaucoma Therapeutics Market size was estimated at USD 7,391.22 million in 2021 and expected to reach USD 7,987.70 million in 2022, and is projected to grow at a CAGR 8.32% to reach USD 11,942.29 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Open-Angle Glaucoma Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Non-PGAs and PGAs.
Based on Drug Class, the market was studied across Bimatoprost, Latanoprost, Travoprost, and Unoprostone.
Based on End Users, the market was studied across Ambulatory Surgical Centers, Hospitals, and Ophthalmic Clinics.
Based on Distribution Channel, the market was studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Open-Angle Glaucoma Therapeutics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Open-Angle Glaucoma Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Open-Angle Glaucoma Therapeutics Market, including AbbVie Inc., Aerie Pharmaceuticals Inc, Alcon Inc., AqueSys, Bausch Health Co Inc, D.Western Therapeutics Institute Inc, EyePoint Pharmaceuticals,Inc, Fera Pharmaceuticals, Hikma Pharmaceuticals Plc, Iridex Corporation, Laboratories Sophia, Merck and Co. Inc., Nicox SA, Novartis AG, Ocuphire Pharma Inc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., PharmaMar SA, Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd, Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Open-Angle Glaucoma Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Open-Angle Glaucoma Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Open-Angle Glaucoma Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Open-Angle Glaucoma Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Open-Angle Glaucoma Therapeutics Market?
6. What is the market share of the leading vendors in the Global Open-Angle Glaucoma Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the Global Open-Angle Glaucoma Therapeutics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of glaucoma globally
5.1.1.2. Increasing demand for combustion drugs
5.1.1.3. Improving diagnostic tools to detect glaucoma
5.1.2. Restraints
5.1.2.1. Rising drug recalls for glaucoma treatments
5.1.3. Opportunities
5.1.3.1. Growing approvals for open-angle glaucoma therapies
5.1.3.2. Rising introduction of advanced open-angle glaucoma therapies
5.1.4. Challenges
5.1.4.1. Advances in glaucoma surgeries
5.2. Cumulative Impact of COVID-19
6. Open-Angle Glaucoma Therapeutics Market, by Product
6.1. Introduction
6.2. Non-PGAs
6.3. PGAs
7. Open-Angle Glaucoma Therapeutics Market, by Drug Class
7.1. Introduction
7.2. Bimatoprost
7.3. Latanoprost
7.4. Travoprost
7.5. Unoprostone
8. Open-Angle Glaucoma Therapeutics Market, by End Users
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Hospitals
8.4. Ophthalmic Clinics
9. Open-Angle Glaucoma Therapeutics Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Americas Open-Angle Glaucoma Therapeutics Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Open-Angle Glaucoma Therapeutics Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Open-Angle Glaucoma Therapeutics Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. AbbVie Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Aerie Pharmaceuticals Inc
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Alcon Inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. AqueSys
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Bausch Health Co Inc
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. D.Western Therapeutics Institute Inc
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. EyePoint Pharmaceuticals,Inc
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Fera Pharmaceuticals
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Hikma Pharmaceuticals Plc
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Iridex Corporation
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Laboratories Sophia
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Merck and Co. Inc.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Nicox SA
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Novartis AG
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Ocuphire Pharma Inc
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Otsuka Pharmaceutical Co. Ltd.
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Pfizer Inc.
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. PharmaMar SA
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Santen Pharmaceutical Co. Ltd.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Sun Pharmaceutical Industries Ltd
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Taro Pharmaceutical Industries Ltd.
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. Teva Pharmaceutical Industries Ltd.
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services
14.23. Viatris Inc.
14.23.1. Business Overview
14.23.2. Key Executives
14.23.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing